Meitheal Pharmaceuticals, Inc.

BREAKING NEWS: Meitheal Pharmaceuticals Announces FDA Approval & Launch of Liraglutide Injection     We’re excited to share that Meitheal Pharmaceuticals has received FDA approval for and launched its generic liraglutide injection (18mg/3mL).  Liraglutide injection is a GLP-1 receptor agonist used to improve glycemic control in adults and pediatric patients (10 years and older) with type 2 diabetes. With a growing demand for GLP-1 treatment options, our launch provides patients and healthcare providers with a more accessible, reliable alternative at a time when multiple branded products are in active shortage.    This milestone marks Meitheal’s first commercial diabetes medication and injector pen product, further expanding our commitment to delivering high-quality, life-changing medicines. We remain dedicated to ensuring a sustainable, affordable supply of critical treatments to meet patient needs.     Learn more about this launch and our mission to improve access to essential medicines: https://lnkd.in/gkgEKdDV

While our team of Dave Ward, Chris Martella and Angie Brym are in Houston at AMCP 2025 and ready to speak with those attending, you can see for yourself how Meitheal is driving greater accessibility to high-quality, cost-effective medications.

AMCP 2025 Houston, TX March 31st - April 3rd, 2025 Houston is known for its rich history, diverse culture, and leadership in healthcare innovation. Home to the world’s largest medical center, Houston is the perfect setting for the AMCP 2025 conference, where market leaders are gathering to discuss the future of the managed care pharmacy industry. Dave Ward, Chris Martella and Angie Brym will be representing Meitheal at AMCP 2025. If you’re attending AMCP 2025, be sure to connect with Dave, Chris, or Angie to learn more about our commitment to healthcare access for all. We look forward to insightful discussions and meaningful partnership. #managedcare #pharma #healthcare

PCRS 2025 Indian Wells, CA March 19-22, 2025 Indian Wells, renowned for its world-class tennis, will once again serve as the premier gathering place for the Pacific Coast Reproductive Society’s annual conference. Meitheal Fertility is excited to be part of PCRS 2025. Visit us at booth 417 to connect with our team and discover how Meitheal Fertility delivers accessibility and affordable solutions in the fertility space. We are committed to offering life-changing medicines for the common good. #Fertility #ReproductiveCare #Pharma

DCAT WEEK 2025 (Drug, Chemical & Associated Technologies Association) New York City, NY March 17-20, 2025 The City That Never Sleeps will once again be abuzz as New York City hosts DCAT Week 2025 from March 17th - 20th. The Meitheal team is looking forward to participating in this premier event that unites top leaders in the global bio/pharmaceutical manufacturing industry. As we continue to expand our impact, Meitheal remains committed to delivering healthcare solutions for the common good. #DCAT #pharmaceuticals #biopharma

Meitheal Pharmaceuticals introduces Alprostadil Injection, USP (500 mcg/mL) in vial form. Alprostadil is a vasodilator used for palliative therapy until surgery can be performed in neonates who have congenital heart defects. "Meitheal is proud to expand its portfolio of sustainably manufactured and affordably priced generic injectables with the introduction of Alprostadil Injection, USP in vial form. Amid ongoing product shortages, we are committed to accelerating the availability of critical medicines and launching the sole vial presentation for the 500 mcg/mL strength, which may offer healthcare providers a safer alternative for handling and administration to patients," said Brett Novak, SVP of Commercial Operations at Meitheal Pharmaceuticals. "With over $100 million invested in generic R&D over the past six years through our parent company, Nanjing King Friend (NKF), Meitheal remains dedicated to advancing efficient drug development and commercialization to improve patient access to life-changing treatments." Read more about this exciting launch: https://lnkd.in/g6VNKwR5